IFNA2 and colorectal carcinoma: Similarly, low-dose combination of two FDA-approved epidrugs, 5-Aza (A) and romidepsin (R), with IFNα2 (ARI) suppresses the aggressiveness of CRC by augmenting DCs function 194.